Home » Stocks » NCNA


Stock Price: $4.73 USD -0.24 (-4.83%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $4.70 -0.03 (-0.63%) Oct 30, 5:57 PM

Stock Price Chart

Key Info

Market Cap 153.44M
Revenue (ttm) n/a
Net Income (ttm) -27.36M
Shares Out 32.44M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $4.73
Previous Close $4.97
Change ($) -0.24
Change (%) -4.83%
Day's Open 4.96
Day's Range 4.62 - 5.04
Day's Volume 183,519
52-Week Range 3.81 - 10.59

More Stats

Market Cap 153.44M
Enterprise Value 93.78M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.44M
Float 27.73M
EPS (basic) n/a
EPS (diluted) -0.63
FCF / Share -0.99
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.24M
Short Ratio 1.45
Short % of Float 4.48%
Beta 1.04
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.43
Revenue n/a
Operating Income -35.70M
Net Income -27.36M
Free Cash Flow -32.06M
Net Cash 59.65M
Net Cash / Share 1.84
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -24.47%
ROE -33.21%
ROIC -312.40%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(282.33% upside)
Current: $4.73
Target: 18.08
*Average 12-month USD price target from 7 stock analysts.

Financial Performance

Financial numbers in millions GBP.

Financial Overview

Operating Income-25.68-22.03-24.04-9.05-6.91
Net Income-21.41-13.84-23.09-6.05-5.33
Shares Outstanding32.2331.8131.8131.81-
Earnings Per Share-0.66-0.43-0.89-0.25-0.22
Operating Cash Flow-23.85-16.45-8.99-10.37-5.50
Capital Expenditures-1.26-1.62-1.10-0.55-0.40
Free Cash Flow-25.11-18.07-10.09-10.92-5.89
Cash & Equivalents51.9676.9786.7019.9929.19
Total Debt0.81----
Net Cash / Debt51.1676.9786.7019.9929.19
Book Value63.5281.5993.4225.2429.96
Numbers in millions GBP, except per-share numbers.

Company Profile

Company Details

Full Name NuCana PLC
Country United Kingdom
Employees 29
CEO Hugh Stephen Griffith

Stock Information

Ticker Symbol NCNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NCNA
IPO Date September 28, 2017


NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.